Skip to content

Author

E. Tai

We have 4 of 39 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

Pre-emptive pharmacogenomics testing in clinical practice: A pilot implementation in Singapore.

AIMS Pre-emptive pharmacogenomics (PPGx) testing holds promise for optimizing drug therapy, but uptake remains limited in Asia. This pilot study aimed to assess the feasibility of PPGx uptake into clinical practice and its impact on prescribing in an Asian healthcare setting. METHODS A prospective, multicentre pilot...

E. Lo, Ming-Chua Hui, Dennis Chua et al. · 0 citations
Sep 2026

Uncovering dysbetalipoproteinemia in a patient initially diagnosed with familial hypercholesterolemia: The role of whole exome sequencing and longitudinal follow-up in diagnostic precision and care.

An 18-year-old woman with severe dysbetalipoproteinemia with severe ApoE deficiency associated with early onset of clinical manifestations, elevated remnant cholesterol, and a favorable therapeutic response to a combination of statins and ezetimibe is reported.

S. Pek, S. Dissanayake, H. Chen et al. · 0 citations
Sep 2026

Prevalence of pharmacogenomically implicated prescriptions in multi-ethnic populations in Singapore.

Pharmacogenomically implicated medication prescriptions are common in Singapore and are particularly prevalent in elderly populations, with males prescribed these medications earlier in life than females and Indians and Malays were more likely to be prescribed these medicines at a younger age than Chinese.

Zavier Zhe Xuan Loo, Zhen-Hua Li, Sean Zhuo Xuan Lee et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.